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What It Is
Sudafed PE Nasal Decongestant is a new OTC
version of Sudafed Nasal Decongestant.
It
contains 10 mg of phenylephrine instead of 30 mg
of pseudoephedrine as the only active ingredient.

How It Works
Phenylephrine is a sympathomimetic amine
that primarily exhibits direct alpha-adrenergic
receptor stimulation.
Because of its potent
vasoconstrictor effects on nasal vasculature, it
causes shrinkage of nasal mucosa, thereby acting
as a decongestant.1,2

Indications
The indications for Sudafed PE are the same as
the indications for Sudafed.
These include
temporary relief of nasal congestion due to the
common cold, hay fever, or other upper
respiratory allergies, and nasal congestion
associated with sinusitis. It is also indicated for
temporary relief of sinus congestion and pressure.3

How Supplied
Sudafed PE is supplied in a tablet dosage form
in boxes of 18, 36, and 72 tablets. The AWP for a
box of 18 tablets is $4.29 as compared with
Sudafed in a box of 24 tablets at $4.29.4

blanching of the skin, respiratory distress,
hypertension, precordial pain, and pilomotor
response.1

Drug Interactions
Nonselective
beta-blockers,
methyldopa,
reserpine,
guanethidine,
and
tricyclic
antidepressants may increase hypertensive effects
of phenylephrine. MAO inhibitors potentiate
cardiac and pressor effects of phenylephrine.
Concurrent use of any of these agents should be
avoided. Coadministration of phenylephrine with
cocaine may cause malignant arrhythmias, and
use with ephedra or yohimbe can result in
excessive CNS stimulation.1,5

Contraindications
Sudafed
PE
is
contraindicated
in
hypersensitivity to phenylephrine or any
component of the formulation, as well as other
sympathomimetic drugs; in severe hypertension,
ventricular tachycardia, and severe coronary
artery disease. It is contraindicated with MAOI
therapy.

Precautions

The dosage for adults and children 12 years of
age and over is one tablet taken every 4 hours
with not more than six doses in a 24 hour period.
For children under 12 years, the advice of a
physician must be sought.3

Sudafed PE should be used with caution and a
physician should be consulted prior to use in
patients with hyperthyroidism, diabetes mellitus,
hypertension, ischemic heart disease, and urinary
retention.
Patients experiencing nervousness,
dizziness, or insomnia during current use should
discontinue treatment. Treatment with Sudafed
PE should cease whenever symptoms persist for
seven days or are accompanied by fever.1,3

Adverse Effects

Use In Pregnancy

As described in the product information,
nervousness, dizziness, and insomnia may occur
and warrant discontinuation of Sudafed PE.3
Other systemic effects of phenylephrine include
anxiety, weakness, tremor, headache, pallor or

Phenylephrine is a Pregnancy Category C
drug. Therefore, use during pregnancy should be
avoided.5

Dosage
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Manufacturer
Pfizer
235 East 42nd Street
New York, NY 10017
800-438-1985
www.pfizer.com

Commentary
Pfizer’s decision to market Sudafed PE results
from the current and ongoing problem of
methamphetamine
manufacturing
using
pseudoephedrine as a chemical precursor. Pfizer
will continue to market Sudafed with its
pseudoephedrine content. This action enables
Pfizer to maintain an overt “front shelf” presence
of its Sudafed PE product wherever over-thecounter products are sold. At the same time,
Pfizer retains the broad availability of Sudafed
even in states requiring pseudoephedrine product
storage behind-the-counter.
Sudafed PE is
currently available at the wholesale distribution
level.
The Meth Watch program sponsored by the
Consumer Healthcare Products Association
(CHPA) is active in several states. Its goal is to
promote cooperation between retailers and law
enforcement to prevent diversion of legitimate
products for purposes of methamphetamine
production. The program encourages restricted
access and observation of precursor ingredient
purchase such as over-the-counter cold, cough, or
allergy medicines containing pseudoephedrine or
ephedrine as well as household supply items such
as rubbing alcohol, lye, iodine, and others used to
manufacture methamphetamine.
Please see
Detail-Document #200809, Methamphetamine
and the Meth Watch Program for more
information on this topic.
The substitution of phenylephrine for
pseudoephedrine will eliminate the chemical
conversion possibility of methamphetamine
production from Sudafed PE.
The nasal decongestant efficacy of oral
phenylephrine vs. pseudoephedrine may not be
the same. Pharmacologically, phenylephedrine is
a direct alpha-adrenergic agonist in therapeutic
doses whereas pseudoephedrine has both alphaand, to a lesser degree, beta-adrenergic activity.
Pseudoephedrine also exerts an indirect effect
causing release of norepinephrine from storage
sites.1,2,5 Phenylephrine has a shorter elimination

half-life
of
2.5
hours
compared
to
pseudoephedrine with a nine to 16 hour half-life.5
Furthermore, it is believed that orally
administered phenylephrine undergoes first-pass
hepatic metabolism, whereas pseudoephedrine
does not.6 In a nasal airway resistance study
conducted by Bickerman, the single-dose efficacy
of pseudoephedrine 60 mg, phenylpropanolamine
40 mg, phenylephrine 10 mg, and placebo were
compared.
Pseudoephedrine
and
phenylpropanolamine decreased nasal airway
resistance whereas phenylephrine was no more
effective than placebo.7 The FDA has classified
phenylephrine in an oral dose of 10 mg as
effective and safe.8
With phenylephrine’s first-pass metabolism
and its short elimination half-life, yet its
unopposed pure alpha-agonist effects, it is
unknown if it presents a more favorable safety
profile than pseudoephedrine.5,6 The lowest dose
that may elevate blood pressure in normotensive
patients, as identified in a single study, was 45 mg
or higher.9 No clear evidence exists that either
drug is safer in patients with hypertension.
Randomized controlled trials or meta-analyses
directly
comparing
phenylephrine
with
pseudoephedrine are not available. Both drugs
can prolong QT intervals.10
As identified in the product label, Sudafed PE
should be used with caution and a physician
should be consulted prior to use in patients with
hyperthyroidism, diabetes mellitus, hypertension,
ischemic heart disease, and urinary retention.
Patients experiencing nervousness, dizziness, or
insomnia during current use should discontinue
treatment. Treatment with Sudafed PE should
cease whenever symptoms persist for seven days
or are accompanied by fever.1,3
Users of this document are cautioned to use their own
professional judgment and consult any other necessary
or appropriate sources prior to making clinical
judgments based on the content of this document. Our
editors have researched the information with input
from experts, government agencies, and national
organizations. Information and Internet links in this
article were current as of the date of publication.
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